Literature DB >> 15736425

Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.

A Calascibetta1, D Cabibi, A Martorana, G Sanguedolce, L Rausa, S Feo, G Dardanoni, R Sanguedolce.   

Abstract

BACKGROUND: Microsatellite instability (MSI) is a biological characteristic of most tumours, being involved in 85% of hereditary non-polyposis colorectal cancer (HNPCC). It also occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC appears to be caused by germline mutations in mismatch repair (MMR) genes, which are responsible for repairing single base-pair mismatches. MSI is also associated with a better response of CRC to adjuvant chemotherapy with fluoropyrimidines. We investigated any relationship between the MSI status and the TSmRNA expression, the polymorphisms of 5-Fluorouracil (5-FU cellular target, the enzyme thymidylate synthase (TS) and TS expression evaluated by means of immunohistochemistry.
MATERIALS AND METHODS: A series of 80 colorectal cancers was evaluated for MSI and polymorphisms in the 3'UTR and the 5'UTR of the TS gene by a PCR assay. TSmRNA was quantified by real-time PCR and the TS expression by immunohistochemical assay.
RESULTS: There was no significant association between the polymorphisms in the TS gene and the MSI or between the TSmRNA expression and the MSI status. CRC with a 3R/3R or 2R/3R genotype showed a significantly higher TSmRNA expression than those with the 2R/2R genotype (p = 0.001 and p = 0.028, respectively). Another significant association was found between the TSmRNA expression and the TS immunohistochemical determination (p = < 0.05). No association was found between the polymorphism of the 3'UTR and the TSmRNA expression.
CONCLUSION: Our data show that there is no association between MSI status and the polymorphisms in the 3' and 5' UTRs and the TS expression. Tumour samples displaying the 3R/3R or 2R/3R genotype of TS have higher TSmRNA levels than the 2R/2R genotype. Polymorphic variant of the 3'UTR does not influence the TSmRNA level. We found a relationship between the TSmRNA expression, evaluated by real-time PCR, and with the TS level determined by immunohistochemical assay. Thus, genotyping of the 5'UTR and quantification of the TSmRNA expression in human CRC could be considered as predictors for response to SFU-based chemotherapy. The evaluation of the TS expression by means of immunohistochemistry assay remains a safe and reliable assay in CRC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15736425

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.

Authors:  Jian-Wei Lu; Chang-Ming Gao; Jian-Zhong Wu; Hai-Xia Cao; Kazuo Tajima; Ji-Feng Feng
Journal:  J Hum Genet       Date:  2006-01-20       Impact factor: 3.172

2.  Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.

Authors:  Sudha Mannava; Vladimir Grachtchouk; Linda J Wheeler; Michael Im; Dazhong Zhuang; Elena G Slavina; Christopher K Mathews; Donna S Shewach; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2008-06-03       Impact factor: 4.534

Review 3.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

4.  Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.

Authors:  Søren A Jensen; Ben Vainer; Mogens Kruhøffer; Jens B Sørensen
Journal:  BMC Cancer       Date:  2009-01-20       Impact factor: 4.430

5.  Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.

Authors:  F Graziano; A Ruzzo; F Loupakis; D Santini; V Catalano; E Canestrari; P Maltese; R Bisonni; L Fornaro; G Baldi; G Masi; A Falcone; G Tonini; P Giordani; P Alessandroni; L Giustini; B Vincenzi; M Magnani
Journal:  Br J Cancer       Date:  2008-08-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.